SCHEMBL22822211

SCHEMBL22822211

CSc1ncccc1C(=O)Nc1nc(-c2cccc(Nc3ccccc3)c2)cs1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.54
RAB9A P51151 7/20 0.54
NPC1 O15118 6/20 0.54
GAA P10253 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.52
ALDH1A1 P00352 2/20 0.52
SLC2A1 P11166 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
KDM4E B2RXH2 3/20 0.51
KMT2A Q03164 6/20 0.50
MEN1 O00255 4/20 0.50
MAPK1 P28482 1/20 0.49
LMNA P02545 2/20 0.48
PKM P14618 1/20 0.48
HTT P42858 2/20 0.48
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22801092 0.91 MAPT (0.48) MAPTRAB9ANPC1GAANPSR1
SCHEMBL22801102 0.90 CFTR (0.51) MAPTRAB9ANPC1GAANPSR1
SCHEMBL22801068 0.90 SLC2A1 (0.56) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL22801078 0.90 MAPT (0.59) MAPTRAB9ANPC1NPSR1SMN1; SMN2
SCHEMBL22801045 0.89 CSNK2A2 (0.49) MAPTRAB9ANPC1GAANPSR1
SCHEMBL22801030 0.87 SLC2A1 (0.63) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL22801077 0.87 MAPT (0.46) MAPTRAB9ANPC1GAANPSR1
SCHEMBL22801071 0.86 KMT2A (0.46) MAPTRAB9ANPC1GAANPSR1
SCHEMBL22801028 0.86 MAPT (0.63) MAPTRAB9ANPC1GAASMN1; SMN2
SCHEMBL22801044 0.85 KMT2A (0.56) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200399264-A1 4-SUBSTITUTED-2-THIAZOLE AMIDES AS ANTIVIRAL AGENTS NATIONAL INSTITUTES OF HEALTH 2020-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399264-A1 4-SUBSTITUTED-2-THIAZOLE AMIDES AS ANTIVIRAL AGENTS MAVS, ZC3HAV1, EIF2AK2 MAPT 347/4885RAB9A 1589/4885NPC1 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.